Sophia Genetics, a provider of data-driven medicine and cloud-native healthcare technology, has unveiled the latest version of its Sophia DDM platform.
Sophia DDM is a platform designed to analyse complex genomic and multimodal data. It provides real-time, actionable insights for a wide network of hospitals, laboratories, and biopharma institutions around the world.
The next-generation platform features an upgraded architecture that enhances its ability to process large datasets more efficiently.
It also improves the user experience by integrating access to advanced multimodal analytics modules.
The first generation of the Sophia DDM platform was launched in 2015. It has helped advance data-driven medicine on a global scale and aid in enhancing patient care through data.
Last month, the technology received the CE mark approval under the European Union’s In Vitro Diagnostic Regulation (IVDR).
This updated version features a new web-based architecture designed for greater efficiency, the company said.
It uses microservices and the latest in cloud computing and GPU technologies from partners like Nvidia and Microsoft.
According to the Swiss healthcare technology company, faster data processing enhances computational efficiency and accelerates the delivery of insights.
It will also benefit customers with reduced turnaround times, receiving results more quickly from data upload to analysis.
Additionally, the improved data processing capabilities will help include new features, such as the upcoming whole genome sequencing (WGS) application slated for release later this year.
This advancement also supports expanded multimodal analytics, allowing for the handling of more complex and substantial datasets across various data types.
Sophia Genetics chief scientific officer Zhenyu Xu said: “Our decentralised, multimodal analytics platform supports customers and helps break data silos by creating a global community where knowledge is safely and securely shared amongst users.
“The new generation of our Sophia DDM platform is revolutionizing the user experience by blending our powerful AI algorithms with multimodal data to produce meaningful insights to further the field of precision medicine.”
Furthermore, the new generation of the Sophia DDM platform will allow users to access the integrated capabilities for genomic, radiomic, and multimodal analytics within a single workspace.
This unified approach allows customers to choose the analytics modules that best meet their needs, Sophia Genetics added.
In June, the healthcare technology company unveiled its new Residual Acute Myeloid (RAM) application, which expands its comprehensive oncology portfolio.
